Mix and Match: One-step activation for targeted drug delivery

This project aims to develop a novel, efficient method for on-demand attachment of targeting ligands to nanocarriers, enhancing drug delivery efficacy while reducing toxicity in cancer therapies.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

Current clinically approved drug delivery systems, such as liposome, PEGylated liposome, and polymeric micelle, predominantly rely on passive accumulation within tumor tissues by diffusion through the defective tumor vessels during circulation. The targeting efficacy toward cancer cells is very limited due to their inadequate interaction with cancer cells.

Limitations of Current Methods

The attachment of targeting ligands to nanocarriers has demonstrated its effectiveness in enhancing binding affinity and, consequently, facilitating cellular uptake via receptor-mediated endocytosis. However, the conventional methods employed for ligand attachment suffer from:

  1. Harsh conditions
  2. Low efficiency
  3. Limited control over ligand orientation

These drawbacks compromise the targeting performance and are believed to result in the current absence of a targeted drug delivery system on the market.

Proposed Solution

In this project, we propose a simple, efficient, and mild attachment method to spontaneously activate on-demand nanocarriers.

Potential Impact

This innovative approach has the potential to have a multi-level effect:

  1. Revolutionize various fields, including drug delivery, diagnostics, and nanotechnology, by providing advanced tools for targeted therapies and diagnostics.
  2. Develop novel methodologies that can be applied to existing technologies to enhance uptake, localization, and efficacy while minimizing systemic toxicity.

This could potentially shift the health-economic balance for some treatments which were previously inaccessible.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-9-2024
Einddatum28-2-2026
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • STICHTING RADBOUD UNIVERSITEITpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Remotely actuated re-shaped nanocarriers for tumour targeting

Developing remotely actuated, anisotropic metal/polymer hybrid nanoparticles for targeted drug delivery in cancer to enhance therapeutic efficacy and minimize side effects.

€ 150.000
ERC Proof of...

Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug delivery

This project aims to innovate lipid-based drug delivery by developing novel functionalization methods to enhance therapeutic efficiency while overcoming PEGylation drawbacks.

€ 150.000
ERC Starting...

Breaching the protective cancer stroma with radiotherapy-responsive liposomes

This project aims to enhance liposomal drug delivery in pancreatic cancer by integrating radiocatalytic nanomaterials for controlled drug release and improved tissue permeability through radiotherapy.

€ 1.942.158
ERC Starting...

Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision

Develop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage.

€ 1.479.321
ERC Advanced...

Functional Nanoscale Therapeutics

Develop functional hybrid nanoscale medicines to enhance intracellular delivery of mRNA and combat nanoscale pathogens, aiming for advanced therapies against diseases like cancer.

€ 2.499.796

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377
EIC Pathfinder

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

€ 2.966.695
EIC Transition

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.

€ 2.498.963